PRODUCT FILTER
Categories
Type
Type

Nebivolol STELLA 5 mg
Rx

Nebivolol is a racemate of two enantiomers, d-nebivolol and or l-nebivolol. It combines two pharmacological activities: Competitive and selective beta-receptor antagonism and mild vasodilation.

Pack size Box of 30 tablets, 50 tablets.
Shelf-life 36 months
Composition Nebivolol
Dosage forms and strengths Tablet: 5 mg
Product code :

PRESCRIBING INFORMATION

Indications:

Treatment of hypertension.

Dosage:

  • Adults: The dose is one tablet (5 mg) daily, preferably at the same time of the day.
  • Patients with renal insufficiency, patients over 65 years: the recommended starting dose is 2.5 mg daily. If needed, the daily dose may be increased to 5 mg.

Usage:

Nebivolol STELLA 5 mg is administered orally.

  • Known hypersensitivity to any of the active substance or excipients.
  • Liver insufficiency or liver function impairment.
  • Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring i.v. inotropic therapy.
  • Sick sinus syndrome, including sino-atrial block.
  • Second and third degree heart block (without a pacemaker).
  • History of bronchospasm and bronchial asthma.
  • Metabolic acidosis.
  • Untreated phaeochromocytoma.
  • Bradycardia (heart rate < 60 bpm prior to start therapy).
  • Hypotension (systolic blood pressure < 90 mmHg)

Headache, dizziness, paresthesia, dyspnea, constipation, nausea, diarrhea, tiredness and edema.

  • The beta-adrenergic antagonist should be discontinued at least 24 hours before surgery.
  • Beta-adrenergic antagonists should not be used in patients with untreated congestive heart failure, unless their condition has been stabilized.
  • In patients with ischemic heart disease, treatment with a beta-antagonist should be discontinued gradually, i.e. over 1 – 2 weeks.
  • Beta-adrenergic antagonists should be used with caution In patients with Raynaud’s disease or syndrome, intermittent claudication; patients with first degree heart block, Prinzmetal’s angina; diabetic patients and patients with chronic obstructive pulmonary disorders.
  • Nebivolol should not be used during pregnancy unless clearly necessary. Administration of nebivolol is not recommended during breastfeeding.
  • Patients should be aware of how they react to drug before driving or operating machinery as dizziness and fatigue may occasionally occur.